Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
NCT01546987 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer when combined with hormone therapy. Studying quality-of-life in patients having cancer treatment may help identify the intermediate- and long-term effects of treatment on patients with prostate cancer. PURPOSE: This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.
Conditions Studied
Interventions
- RADIATION Radiation therapy
- DRUG GnRH agonist
- DRUG Anti-androgen
- DRUG TAK-700
Study Locations (20)
California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park
- Mercy San Juan Medical Center — Carmichael
- Veterans Administration Long Beach Medical Center — Long Beach
- Los Angeles County-USC Medical Center — Los Angeles
- University of Southern California/Norris Cancer Center — Los Angeles
- Cedars-Sinai Medical Center — Los Angeles
- Pomona Valley Hospital Medical Center — Pomona
- Rohnert Park Cancer Center — Rohnert Park
- Sutter Cancer Centers Radiation Oncology Services-Roseville — Roseville
- Sutter General Hospital — Sacramento
- University of California At San Diego — San Diego
- UCSF-Mount Zion — San Francisco
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara
- Kaiser Permanente Cancer Treatment Center — South San Francisco
- Stanford University Hospitals and Clinics — Stanford
Alabama
- The Kirklin Clinic at Acton Road — Birmingham
- University of Alabama at Birmingham — Birmingham
Arizona
- Arizona Oncology-Deer Valley Center — Phoenix
- Arizona Oncology Services Foundation — Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2012-05 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01546987
The ClinicalTrials.gov registry entry for NCT01546987 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions — of which Radiation therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01546987 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Alabama, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01546987 about?
NCT01546987 is a clinical study titled "Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective...
What is the current status of trial NCT01546987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2012-05. Estimated completion is 2025-09-04.
What conditions does trial NCT01546987 study?
This clinical trial studies the following conditions: Prostate Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01546987?
The interventions under investigation include: Radiation therapy (RADIATION), GnRH agonist (DRUG), Anti-androgen (DRUG), TAK-700 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01546987?
This trial is sponsored by Radiation Therapy Oncology Group, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01546987 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.